These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 19265748

  • 1. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1.
    Grabowski GA, Kacena K, Cole JA, Hollak CE, Zhang L, Yee J, Mistry PK, Zimran A, Charrow J, vom Dahl S.
    Genet Med; 2009 Feb; 11(2):92-100. PubMed ID: 19265748
    [Abstract] [Full Text] [Related]

  • 2. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
    Andersson H, Kaplan P, Kacena K, Yee J.
    Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
    [Abstract] [Full Text] [Related]

  • 3. Enzyme replacement and substrate reduction therapy for Gaucher disease.
    Shemesh E, Deroma L, Bembi B, Deegan P, Hollak C, Weinreb NJ, Cox TM.
    Cochrane Database Syst Rev; 2015 Mar 27; 2015(3):CD010324. PubMed ID: 25812601
    [Abstract] [Full Text] [Related]

  • 4. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment.
    Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, vom Dahl S, Hollak C.
    J Inherit Metab Dis; 2013 May 27; 36(3):543-53. PubMed ID: 22976765
    [Abstract] [Full Text] [Related]

  • 5. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
    Weinreb NJ, Camelo JS, Charrow J, McClain MR, Mistry P, Belmatoug N, International Collaborative Gaucher Group (ICGG) Gaucher Registry (NCT00358943) investigators.
    Mol Genet Metab; 2021 Feb 27; 132(2):100-111. PubMed ID: 33485799
    [Abstract] [Full Text] [Related]

  • 6. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, Batista JL, Cox GF, Mistry PK.
    Mol Genet Metab; 2017 Feb 27; 120(1-2):47-56. PubMed ID: 28040394
    [Abstract] [Full Text] [Related]

  • 7. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 27; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 8. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, Kishnani PS, Kolodny EH, Rosenbloom B, Scott CR, Weinreb N.
    Am J Hematol; 2017 Sep 27; 92(9):929-939. PubMed ID: 28569047
    [Abstract] [Full Text] [Related]

  • 9. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R, Arndt S, Levin JB.
    S Afr Med J; 2004 Aug 27; 94(8):647-51. PubMed ID: 15352589
    [Abstract] [Full Text] [Related]

  • 10. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN.
    J Bone Miner Res; 2007 Jan 27; 22(1):119-26. PubMed ID: 17032149
    [Abstract] [Full Text] [Related]

  • 11. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep 27; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 12. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
    Mistry PK, Weinreb NJ, Kaplan P, Cole JA, Gwosdow AR, Hangartner T.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):66-72. PubMed ID: 21112800
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.
    Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A.
    Am J Med; 2002 Aug 01; 113(2):112-9. PubMed ID: 12133749
    [Abstract] [Full Text] [Related]

  • 14. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).
    Zimran A, Morris E, Mengel E, Kaplan P, Belmatoug N, Hughes DA, Malinova V, Heitner R, Sobreira E, Mrsić M, Granovsky-Grisaru S, Amato D, vom Dahl S.
    Blood Cells Mol Dis; 2009 Aug 01; 43(3):264-88. PubMed ID: 19502088
    [Abstract] [Full Text] [Related]

  • 15. Replacement therapy with imiglucerase for type 1 Gaucher's disease.
    Zimran A, Elstein D, Levy-Lahad E, Zevin S, Hadas-Halpern I, Bar-Ziv Y, Foldes J, Schwartz AJ, Abrahamov A.
    Lancet; 1995 Jun 10; 345(8963):1479-80. PubMed ID: 7769903
    [Abstract] [Full Text] [Related]

  • 16. The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients.
    Deegan P, Khan A, Camelo JS, Batista JL, Weinreb N.
    Orphanet J Rare Dis; 2021 Feb 18; 16(1):92. PubMed ID: 33602299
    [Abstract] [Full Text] [Related]

  • 17. Baseline characteristics of 32 patients with Gaucher disease who were treated with imiglucerase: South African data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Sevittz H, Laher F, Varughese ST, Nel M, McMaster A, Jacobson BF.
    S Afr Med J; 2022 Feb 02; 112(1):13518. PubMed ID: 35140000
    [Abstract] [Full Text] [Related]

  • 18. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase.
    Weinreb N, Taylor J, Cox T, Yee J, vom Dahl S.
    Am J Hematol; 2008 Dec 02; 83(12):890-5. PubMed ID: 18819093
    [Abstract] [Full Text] [Related]

  • 19. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
    Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW.
    Blood Cells Mol Dis; 2000 Aug 02; 26(4):285-90. PubMed ID: 11042029
    [Abstract] [Full Text] [Related]

  • 20. The outcome of clinical parameters in adults with severe Type I Gaucher disease using very low dose enzyme replacement therapy.
    Wilson C, Spearing R, Teague L, Robertson P, Blacklock H.
    Mol Genet Metab; 2007 Aug 02; 92(1-2):131-6. PubMed ID: 17604204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.